A
NVAX icon

Allianz’s Novavax NVAX Stock Holding History

Allianz’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-130
Closed -$1.06K – 539
2026
Q1 		$1.06K Buy
+130
New +$1.18K ﹤0.01% 470

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Allianz's NVAX Position: Q2 2026 in Review

Allianz sold out of Novavax (NVAX) in Q2 2026, closing a stake of 130 shares — an estimated $1.06K sold.

Allianz first reported a position in NVAX in Q1 2026 and held it in 1 quarter. The position peaked at $1.06K in Q1 2026. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Allianz reported no remaining Novavax position as of Q2 2026 after selling out during the quarter.
  • Allianz sold 130 Novavax shares in Q2 2026, an estimated $1.06K.
  • Allianz first reported a position in Novavax in Q1 2026 and held it in 1 quarter.
  • Allianz's Novavax position peaked at $1.06K in Q1 2026.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Allianz's 13F filing for Q2 2026, filed 10 Aug 2026.